Monopar New Long-Term Neurological Efficacy, Safety Data for ALXN1840 in Wilson Disease

Monopar Therapeutics (Nasdaq: MNPR) will present new long-term data for its investigational therapy ALXN1840 in Wilson disease at the 150th American Neurological Association Annual Meeting. The analysis combines data from four clinical trials with 266 patients and a median treatment duration of 2.6 years.

Key findings include statistically significant neurologic improvements sustained over 6 years, measured by UWDRS Parts II and III. Patients who switched from standard of care to ALXN1840 showed additional neurological improvement. The drug demonstrated a favorable safety profile with less than 1% of patients experiencing drug-related neurological serious adverse events across more than 645 patient-years.

https://www.stocktitan.net/news/MNPR/monopar-to-present-new-long-term-neurological-efficacy-and-safety-paji7kyczck7.html